IL-8 as mediator in the microenvironment-leukaemia network in acute myeloid leukaemia

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Kuett, Alexander ^a   Rieger, Christina ^a   Perathoner, Deborah ^a   Herold, Tobias ^a   Wagner, Michaela ^a   Sironi, Silvia ^a   Sotlar, Karl ^a   Horny, Hans Peter ^a   Deniffel, Christian ^a   Drolle, Heidrun ^a   Fiegl, Michael ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 8;

ACUTE MYELOID LEUKEMIA; ADOLESCENT; ADULT; AGED; BONE MARROW; BONE MARROW CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; MALE; MESENCHYMAL STROMA CELL; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL NICHE; SURVIVAL ANALYSIS; TUMOR CELL LINE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; BONE MARROW CELLS; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; HYPOXIA; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-8; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STEM CELL NICHE; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84950279617     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep18411     Document Type: Article

References (36)

1. Liersch, R., Muller-Tidow, C., Berdel, W. E. & Krug, U. Prognostic factors for acute myeloid leukaemia in adults-biological significance and clinical use. Br J Haematol 165, 17-38 (2014).
2. Samudio, I., Fiegl, M. & Andreeff, M. Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. Cancer Res 69, 2163-2166 (2009).
3. Samudio, I. et al. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest 120, 142-156 (2010).
4. Konopleva, M. et al. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 16, 1713-1724 (2002).
5. Fiegl, M. et al. CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure. Blood 113, 1504-1512 (2009).
6. Fiegl, M. et al. Physiological hypoxia promotes lipid raft and PI3K-dependent activation of MAPK 42/44 in leukemia cells. Leukemia 24, 1364-1367 (2010).
7. Parmar, K., Mauch, P., Vergilio, J. A., Sackstein, R. & Down, J. D. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA 104, 5431-5436 (2007).
8. Abdel-Wahab, O. & Levine, R. L. Metabolism and the leukemic stem cell. J Exp Med 207, 677-680 (2010).
9. Drolle, H. et al. Hypoxia regulates proliferation of acute myeloid leukemia and sensitivity against chemotherapy. Leuk Res 39, 779-785 (2015).
10. Kornblau, S. M. et al. Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood 116, 4251-4261 (2010).
11. Kittang, A. O., Hatfield, K., Sand, K., Reikvam, H. & Bruserud, O. The chemokine network in acute myelogenous leukemia: molecular mechanisms involved in leukemogenesis and therapeutic implications. Curr Top Microbiol Immunol 341, 149-172 (2010).
12. Picinich, S. C., Glod, J. W. & Banerjee, D. Protein kinase C zeta regulates interleukin-8-mediated stromal-derived factor-1 expression and migration of human mesenchymal stromal cells. Exp Cell Res 316, 593-602 (2010).
13. Braess, J. et al. Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. Blood 113, 3903-3910 (2009).
14. Buchner, T. et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 24, 2480-2489 (2006).
15. Dohner, H. et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115, 453-474 (2010).
16. Samudio, I., Fiegl, M., McQueen, T., Clise-Dwyer, K. & Andreeff, M. The warburg effect in leukemia-stroma cocultures is mediated by mitochondrial uncoupling associated with uncoupling protein 2 activation. Cancer Res 68, 5198-5205 (2008).
17. Matsushima, K. et al. Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor. J Exp Med 167, 1883-1893 (1988).
18. Campbell, L. M., Maxwell, P. J. & Waugh, D. J. Rationale and Means to Target Pro-Inflammatory Interleukin-8 (CXCL8) Signaling in Cancer. Pharmaceuticals 6, 929-959 (2013).
19. Murphy, C. et al. Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin Cancer Res 11, 4117-4127 (2005).
20. Li, A., Varney, M. L. & Singh, R. K. Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials. Clin Cancer Res 7, 3298-3304 (2001).
21. Yuan, A. et al. Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. Am J Respir Crit Care Med 162, 1957-1963 (2000).
22. Tobler, A. et al. Constitutive expression of interleukin-8 and its receptor in human myeloid and lymphoid leukemia. Blood 82, 2517-2525 (1993).
23. Schinke, C. et al. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells. Blood 125, 3144-3152 (2015).
24. Pastore, F. et al. Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia. J Clin Oncol 32, 1586-1594 (2014).
25. Schwartz, R. S., Mackintosh, F. R., Halpern, J., Schrier, S. L. & Greenberg, P. L. Multivariate analysis of factors associated with outcome of treatment for adults with acute myelogenous leukemia. Cancer 54, 1672-1681 (1984).
26. Schwaighofer, H. et al. Serum levels of interleukin 6, interleukin 8, and C-reactive protein after human allogeneic bone marrow transplantation. Transplantation 58, 430-436 (1994).
27. Tilg, H. et al. Interleukin-8 serum concentrations after liver transplantation. Transplantation 53, 800-803 (1992).
28. Shi, Q., Xiong, Q., Le, X. & Xie, K. Regulation of interleukin-8 expression by tumor-associated stress factors. J Interferon Cytokine Res 21, 553-566 (2001).
29. Kim, K. S., Rajagopal, V., Gonsalves, C., Johnson, C. & Kalra, V. K. A novel role of hypoxia-inducible factor in cobalt chloride- and hypoxia-mediated expression of IL-8 chemokine in human endothelial cells. J Immunol 177, 7211-7224 (2006).
30. Strieter, R. M., Belperio, J. A., Phillips, R. J. & Keane, M. P. CXC chemokines in angiogenesis of cancer. Semin Cancer Biol 14, 195-200 (2004).
31. Huang, S. et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol 161, 125-134 (2002).
32. Ginestier, C. et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 120, 485-497 (2010).
33. Ning, Y. et al. The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models. Mol Cancer Ther 11, 1353-1364 (2012).
34. Sotlar, K. et al. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol 28, 1319-1325 (2004).
35. Herold, T. et al. Isolated trisomy 13 defines a genetically homogenous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis. Blood 124, 1304-1311 (2014).
36. Li, Z. et al. Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. J Clin Oncol 31, 1172-1181 (2013).